Concomitantly, the proportion of tumor-infiltrating regulatory T cells (Tregs, CD25+ FoxP3+), a subset of CD4+ T cells that have pro-tumor influences, was reduced after ZVI@CMC treatment (Figure 6M). The gene discussed is CD4; the disease is neoplasm.